<DOC>
	<DOCNO>NCT01354145</DOCNO>
	<brief_summary>The main purpose study compare cartilage volume loss Baseline visit 24 month treatment patient treat CHONDROITIN SULPHATE ( CONDROSAN ) 1200 mg daily vs. patient treat CELECOXIB 200 mg daily .</brief_summary>
	<brief_title>Study Effect Chondroitin Sulfate Structural Changes Knee Osteoarthritis Patients Assessed MRI</brief_title>
	<detailed_description>To compare long term disease modifiying symptomatic effect Baseline visit 24 month treatment patient treat CHONDROITIN SULPHATE 1200 mg daily vs. patient treat CELECOXIB 200 mg daily .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Individuals either sex , age 40 year Subjects present primary OA knee accord ACR criterion sign synovitis ( warmth , swell effusion OA radiological stage 2 3 accord KellgrenLawrence ; Minimum joint space width ≥2 mm medial femorotibial compartment stand knee Xray VAS pain walk ≥ 40 mm Known allergy CHONDROITIN SULPHATE , hypersensitivity CELECOXIB , demonstrate allergictype reaction sulphonamides , experience asthma , urticaria allergictype reaction take sulphonamides , aspirin ( acetyl salicylic acid [ ASA ] ) , lactose NSAIDs Active malignancy type history malignancy within last five year basal cell carcinoma Increased risk prostate cancer , prostate cancer , history prostate cancer within last five year Subjects bone articular disease ( antecedent and/or current sign ) chondrocalcinosis , Paget 's disease ipsilateral limb target knee , rheumatoid arthritis , aseptic osteonecrosis , gout , septic arthritis , ochronosis , acromegaly , haemochromatosis , Wilson 's disease , osteochondromatosis seronegative spondyloarthropathy , mixed connective tissue disease , collagen vascular disease , psoriasis , inflammatory bowel disease Isolated knee lateral compartment OA define joint space loss lateral compartment Class IV functional capacity use American Rheumatism Association criterion Have surgery low limb arthroscopy , aspiration lavage low limb joint within 180 day Baseline Visit History heart attack stroke , experience serious chest pain related heart disease , serious disease heart congestive heart failure High risk CV event , accord AHA assessment CV risk table History recurrent UGI ulceration active inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) , significant coagulation defect , condition , investigator 's opinion might preclude chronic use CELECOXIB . Subjects may , Investigator 's discretion , take PPI antacid daily require Have diagnose treat oesophageal , gastric , pyloric channel , duodenal ulceration within 30 day prior receive first dose study medication Subjects use corticosteroid ( oral , injectable ; exception intraarticular/soft tissue injection exclusion target knee ) , indomethacin , tramadol , codeine , empracet , therapeutic dose glucosamine CHONDROITIN SULPHATE 12 week precede inclusion Using hyaluronic acid ( intraarticular target knee ) 26 week precede inclusion Using Natural Health Products ( e.g . capsaicin , boswellia , willow bark ) , creams analgesic gel ( e.g . camphor alcohol base gel ) one week precede baseline ; Using Natural Health Products susceptible increase risk bleeding ( e.g . garlic , dong quai , etc . ) one week precede baseline ; Receiving radioactive synovectomy ( target knee ) 12 week precede inclusion ; Subjects receive NSAID want stop study If treatment osteoporosis ( biphosphonates , SERMS , THS ) necessary , continue , unmodified , entire duration study Have use medication MMPinhibitory property ( e.g . tetracycline structurally related compound ) within 28 day prior Baseline Visit Are take lithium carbonate , phenytoin anticoagulant ( exception ASA maximum daily dose 325 mg ) Have receive chondrocyte transplant low extremity joint Use oral topical COXIBs , calcitonin immunosuppressive drug</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>